Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Operating Expenses (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Operating Expenses data on record, last reported at $39.9 million in Q4 2022.

  • For Q4 2022, Operating Expenses fell 43.8% year-over-year to $39.9 million; the TTM value through Dec 2022 reached $130.6 million, down 38.66%, while the annual FY2025 figure was $180.9 million, 6.25% down from the prior year.
  • Operating Expenses reached $39.9 million in Q4 2022 per AVIR's latest filing, up from $16.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $71.0 million in Q4 2021 and bottomed at $4.0 million in Q1 2020.
  • Average Operating Expenses over 3 years is $33.6 million, with a median of $33.8 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: soared 773.42% in 2021, then crashed 70.38% in 2022.
  • A 3-year view of Operating Expenses shows it stood at $28.0 million in 2020, then soared by 153.69% to $71.0 million in 2021, then crashed by 43.8% to $39.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $39.9 million in Q4 2022, $16.3 million in Q3 2022, and $32.3 million in Q2 2022.